Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, are a mainstay of metastatic colorectal cancer (mCRC) treatment. However, a significant number of patients suffer from primary or acquired resistance. RAS mutations are negative predictors of clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasper, Stefan, Reis, Henning, Ziegler, Sophie, Nothdurft, Silke, Mueller, Andre, Goetz, Moritz, Wiesweg, Marcel, Phasue, Jeannette, Ting, Saskia, Wieczorek, Sarah, Even, Anna, Worm, Karl, Pogorzelski, Michael, Breitenbuecher, Sandra, Meiler, Johannes, Paul, Andreas, Trarbach, Tanja, Schmid, Kurt Werner, Breitenbuecher, Frank, Schuler, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542236/
https://www.ncbi.nlm.nih.gov/pubmed/28507280
http://dx.doi.org/10.18632/oncotarget.17438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542236/
https://www.ncbi.nlm.nih.gov/pubmed/28507280
http://dx.doi.org/10.18632/oncotarget.17438

Ejemplares similares